PROQR 테라퓨틱스(PRQR)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.83 (-3.17%), 시가총액 $150.67M, 52주 범위 $1.37 ~ $3.05.
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases.
PROQR 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.
PROQR 테라퓨틱스의 현재 주가는 $1.83 (-3.17%)입니다. XTS에서 실시간 시세와 차트를 확인할 수 있습니다.
PROQR 테라퓨틱스의 시가총액은 약 $150.67M입니다.
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines.